Trials

Trial Namesort ascending Status
ZeNix (B-Pa-L) NC-007 all patients enrolled
TRUNCATE-TB enrolling
Traitement du Sida submitted for publication
TMC207TBC1002 published
TMC207-TiDP13-C209 published
TMC207-TiDP13-208 published
TMC207-TBC211 study in development
TBTC Study 33/iAdhere: AdherenceC in data analysis
TBTC Study 32, Opti-Q enrolling
TBTC Study 31 ACTG 5349 4-month treatment regimens all patients enrolled
TBTC Study 30PK Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis submitted for publication
TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tube submitted for publication
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection published
TBA-354 Phase 1a Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects all patients enrolled
TBA 354 Phase 1b Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects early termination
TB-PRACTECAL in data analysis
STREAM Trial Stage 2 all patients enrolled
STAND all patients enrolled
SQ109-CP001 published
Single Dose, Phase 1 published
SimpliciTB-Pa-M-Z) NC-008 study in development
SimpliciTB all patients enrolled
Safety and efficacy of blocking IL-4 with pascolizumab in patients receiving standard combination therapy for pulmonary tuberculosis (TB): a randomized, double-blind, placebo-controlled, proof-of-conc enrolling
RIFASHORT enrolling
Rifapentine TBTC Study 29 published
ReDEFINe High-Dose RIF for Meningitis in data analysis
Q203 Phase 1b Q203-TB-PI-US002 all patients enrolled
Q203 Phase 1a Q203-TB-PI-US001 in data analysis
PredictTB enrolling
Phase 2b: StAT-TB (Statin Adjunctive Therapy for TB) in data analysis
Phase 2a Study of PBTZ169
Phase 2: IMPACT-TB Safety, Pharmacokinetics & Hematologic Effect of Imatinib enrolling
Phase 2 Telacebec (Q203) EBA enrolling
Phase 2 Safety, Efficacy & Biomarker Response of HDTs Added to Standard Therapy in data analysis
Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients enrolling
Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis published
Phase 1 Safety, Tolerability, and Pharmacokinetics of SPR720 enrolling
Phase 1 Safety, Tolerability and Pharmacokinetics of GSK2556286 enrolling
Phase 1 Safety, Tolerability and Pharmacokinetics of BVL-GSK098 enrolling
Phase 1 Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers in data analysis
Perchlozone tablets submitted for publication
Pediatric PK and Safety Trial Delamanid in MDR TB enrolling
PanACEA-MAMS-TB-01 published
PanACEA-MAMS-TB-01 all patients enrolled
PanACEA - RUNMC - HR1 2007.23011.01 published
OPC-167832 Phase 1 / 2 EBA enrolling
Nix-TB (B-Pa-L) all patients enrolled
Nitzoxanide NZT001 14-day EBA all patients enrolled
NIH: A Phase I Open-Label Trial To Investigate the Pharmacokinetic Interaction Between Rifabutin Or Rifampin And A Single Dose Of TMC207 In Healthy Subjects published
NExT Trial: Bedaquiline - Linezolid with OBR MDR early termination
NexGen EBA enrolling
NCT02836483 A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371. enrolling
NC005 enrolling
NC003 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) enrolling
NC003 enrolling
NC002 Phase II Trial to Evaluate the Efficacy, Safety and Tolerability of the Following: PA-824 Plus Moxifloxacin Plus Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Patients
NC002
NC001 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) submitted for publication
NC001 submitted for publication
NC-005 published
NC-003 published
Multiple Dose, Phase 1 published
Meropenem, Faropenem Phase 2 EBA, TASK-001 published
LMU-IMPH-SQ109-01 published
High-Dose Rifampin published
Faro-WBA submitted for publication
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis in data analysis
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis published
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults enrolling
endTB enrolling
Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers in data analysis
EBA, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis enrolling
Delamanid with OBR for MDR TB in data analysis
Controlled comparison of two moxifloxacin containing treatment shortening regimens with the standard regimen in pulmonary TB all patients enrolled
Celecoxib Clinical Study WBA in data analysis
BTZ-043 Multiple Ascending Dose / EBA study in development
BEAT-TB enrolling
B1171003 published
B1171002 published
B1171001 published
AZD5847 Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis published
ACTG 5343 Bedaquiline - Delamanid with MBT for MDR enrolling
ACTG 5306 Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritona enrolling
ACTG 5306 Phase I Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin enrolling
A Phase IIa, Open Label Study to Determine the EBA, Extended EBA and Pharmacokinetic Study of LL3858 for the Treatment of Newly Diagnosed Sputum Smear-Positive Pulmonary TB study in development
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients enrolling
A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis. all patients enrolled
242-07-204 published
09-0111 N01AI80024C published
Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 study in development